Goldman Sachs has Revised the Stock Investment Rating

Investors are optimistic about the development of covid-19 vaccine candidates. In addition, they are optimistic about the recent large-scale mergers and acquisitions. Technology stocks such as Apple and Tesla have soared in retaliation, driving the three major US indexes to rise in early trading on the 14th. Dow Jones Industrial The index rose 1%, the S&P 500 index rose 1.3%, and the Nasdaq composite index rose nearly 2%.

Based on the strong recovery of global corporate profits, Goldman Sachs has revised the stock investment rating in the next three months to “overweight” and predicted that the global stock market is expected to have a return rate of as high as 9% in the next 12 months. Goldman Sachs said that the new crown pneumonia vaccine is the most important factor affecting the stock market in 2021.

Goldman Sachs strategist Christian Mueller-Glissmann said in the latest report that given the sharp rebound in global corporate profits and the relatively cheap stock prices at present, the stock investment rating for the next three months will be “neutral”. Updating to “plus code”.

Goldman Sachs also pointed out that by the end of 2020, stocks and other assets are more likely to have a procyclical tendency, that is, when the economy is good, the higher the real gross domestic product (GDP), the better corporate profits and stock market performance. .

Mueller-Grisman said that in the short term, if the US presidential election and the uncertainty of global growth outlook rise, it will benefit the stock markets outside the US, but in the medium term, structural growth stocks are more weighted. It is expected to support the S&P 500 index.

Goldman Sachs pointed out that the “most important catalyst” for reducing short-term stock market risks and stimulating stock market optimism in 2021 is to further determine when the new crown pneumonia vaccine will be available and how to deploy the vaccine.

Goldman Sachs predicts that global stock markets are expected to have “single-digit high-end” gains in the next 12 months.

According to the Goldman Sachs report, other short-term risks facing the stock market include diminishing utility of the US fiscal stimulus, uncertainty in the US presidential election, an increase in confirmed cases of new crown pneumonia, and fluctuations in oil prices.

Reviewer overview

Goldman Sachs has Revised the Stock Investment Rating - /10

Summary

0 Bad!